[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dr. Hang Wun Raymond Li\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100634213","phase-3-arterial-vascular-effects-of-estetrol-drospirenone-combined-oral-contraceptive-pill-100634213",false,"NCT07536763","Arterial Vascular Effects of Estetrol-drospirenone Combined Oral Contraceptive Pill","Effect of Estetrol-drospirenone Combined Oral Contraceptive Pill on Arterial Vascular Risks","Inclusion Criteria:\n\n* Aged between 18 and 49 years inclusive\n* Considering to use the COC pill for contraception or treatment of menstrual disorders\n\nExclusion Criteria:\n\n* Being diagnosed with menopause\n* Having contraindications to COC, including (but not confined to) hypertension, diabetes mellitus with complications, history of ischaemic heart disease, thromboembolism, stroke, severe liver disease, oestrogen-sensitive cancers, undiagnosed abnormal uterine bleeding, smokers aged 35 years or above, or having body mass index \\>=35 kg\u002Fm2\n* Planning to get pregnant in the coming 1 year\n* Having been pregnant in the past 3 months\n* Having been on COC or hormone replacement therapy in the past 3 months (those who had been on these agents can stop these for 3 months as wash-out period before being recruited; this concurs with other similar studies in the literature)\n* Having been on anti-hypertensive, anti-diabetic or lipid-lowering agents in the past 3 months\n* Refusal to randomization",true,"FEMALE","18 Years","49 Years",{"count":21,"type":22},98,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The goals of this clinical trial are to investigate the effect of the estetrol (E4)-drospirenone combined oral contraceptive (COC) pill on flow-mediated dilatation (FMD) of the brachial artery and pulse wave velocity (PWV), in comparison to the ethinylestradiol (EE)-levonorgestrel COC pill, and to compare their respective effects on blood pressure, chronic inflammatory markers, as well as glycaemic and lipid indices.\n\nThe main questions it aims to answer are:\n\nDoes E4-drospirenone COC have significantly smaller effects then EE-levonorgestrel COC on FMD, PWV, blood pressure, chronic inflammatory markers, as well as glycemic and lipid indices.\n\nResearchers will compare E4-drospirenone to EE-levonorgestrel to see if the former has lower arterial vascular and metabolic risks.\n\nParticipants will:\n\n* be randomised to take E4-drospirenone or EE-levonorgestrel COC pill according to product insert;\n* visit the clinic at baseline and 6 and 12 months post-recruitment for checkups and tests",[28],"Contraception",[30,31,32,33,34],"Estetrol-drospirenone","Ethinylestradiol-levonorgestrel","Combined oral contraceptives","Arterial risks","Metabolic risks","NOT_YET_RECRUITING","2026-04-24",{"date":38,"type":39},"2026-04-27","ACTUAL",{"date":41,"type":22},"2026-07",{"date":43,"type":22},"2029-06",{"name":45,"class":46},"Dr. Hang Wun Raymond Li","OTHER",""]